Life Edit Therapeutics
Michael Lewis is a Scientist II at Life Edit Therapeutics, with previous experience as a Postdoctoral Researcher at the University of North Carolina at Chapel Hill, where research focused on the epigenetics of breast cancer, particularly the role of eRNA producing enhancers in triple negative breast cancer. Prior positions include a Postdoctoral Researcher at the University of Florida, analyzing the Angelman syndrome imprinting defect mouse model, and conducting PhD research on genomic imprinting mechanisms at the Prader-Willi/Angelman syndrome locus. Michael's academic background includes a Ph.D. in Medical Sciences - Genetics and a B.S. in Microbiology and Cell Sciences from the University of Florida, in addition to an A.A. from St. John's River State College.
Life Edit Therapeutics
Life Edit, an ElevateBio company, is a next-generation genome editing company that has built a highly innovative platform with one of the world’s largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The platform allows Life Edit to target any genomic sequence and develop novel human therapeutics for the most challenging genetic diseases by enabling ex vivo engineering for cell therapies and regenerative medicines and in vivo delivery of gene therapies. In addition to developing its own pipeline of cell and gene therapies, Life Edit Therapeutics will continue to strengthen its platform of genome-editing enzymes, provide gene-editing expertise to strategic partners, and form other third-party partnerships to discover and develop new therapies.